Background: PHD2-haplodeficient macrophages (MØs) are promising candidates for the treatment of ischemia-related conditions due to their capacity to modulate the ischemic microenvironment. However, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback